Navigation Links
Cepheid to Present at the Robert W. Baird Growth Stock Conference and the Bank of America Healthcare Conference
Date:5/6/2008

SUNNYVALE, Calif., May 6 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) announced today that the Company will present at the following investor conferences:

-- The Robert W. Baird Growth Stock Conference on May 13 at 12:15 p.m. EDT

at The Four Seasons Hotel in Chicago

-- The Bank of America Healthcare Conference on May 14 at 3:40 p.m. EDT at

The Four Seasons Hotel in Las Vegas

John Bishop, Chief Executive Officer, and Andrew Miller, Senior Vice President, Chief Financial Officer, will provide a corporate overview at each conference.

Live webcasts, along with accompanying presentation slides, may be accessed on Cepheid's Web site at http://www.cepheid.com under Investors: Events: Webcasts and Presentations. A replay of the webcast presentations will be available for 90 days following the live events.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, California, is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080129/LATU101LOGO)


'/>"/>
SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Schedules Teleconference and Webcast for First Quarter 2008 Results
2. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
3. Cepheid Reports Fourth Quarter and Full Year 2007 Results
4. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
5. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
6. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
7. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
8. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
9. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
10. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
11. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... WEST LAFAYETTE, Indiana (PRWEB) , ... ... ... a division of Albany Molecular Research Inc. has further extended its industry ... sector. This service offers state-of-the-art cGMP techniques and methods for the ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
Breaking Biology Technology:
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):